Patents by Inventor Jon E. Chatterton

Jon E. Chatterton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis
    Patent number: 9139834
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: September 22, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • Transferrin/transferrin receptor-mediated siRNA delivery
    Patent number: 9114152
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: August 25, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20150167002
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventors: Jon E. Chatterton, David P. Bingaman
  • LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
    Publication number: 20150165066
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventor: Jon E. Chatterton
  • RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
    Patent number: 9040494
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: May 26, 2015
    Assignee: NOVARTIS AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
    Publication number: 20150057336
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions associated with elevated intraocular pressure (TOP), including glaucoma and ocular hypertension.
    Type: Application
    Filed: September 12, 2014
    Publication date: February 26, 2015
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
    Patent number: 8940887
    Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Alcon Research, Ltd.
    Inventors: Jon E. Chatterton, David P. Bingaman
  • Low density lipoprotein receptor-mediated siRNA delivery
    Patent number: 8937051
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: January 20, 2015
    Assignee: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20140364480
    Abstract: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: March 28, 2014
    Publication date: December 11, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: Jon E. Chatterton, David P. Bingaman
  • RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS
    Publication number: 20140357695
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Application
    Filed: May 5, 2014
    Publication date: December 4, 2014
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20140357694
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: April 3, 2014
    Publication date: December 4, 2014
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20140357696
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Application
    Filed: May 5, 2014
    Publication date: December 4, 2014
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
    Patent number: 8865671
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 21, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-related inhibition of TNF? signaling pathway for treatment of glaucoma
    Patent number: 8865670
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: October 21, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • RNAi-MEDIATED INHIBITION OF SELECT RECEPTOR TYROSINE KINASES FOR TREATMENT OF PATHOLOGIC OCULAR NEOVASCULARIZATION-RELATED CONDITIONS
    Publication number: 20140200259
    Abstract: RNA interference is provided for inhibiton of expression of select receptor tyrosine kinase (RTK) targets in ocular neovascularization-related conditions, including those cellular changes resulting from the signal transduction activity of the select RTK targets that lead directly or indirectly to ocular NV, abnormal angiogenesis, retinal vascular permeability, retinal edema, diabetic retinopathy particularly proliferative diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, sequela associated with retinal ischemia, and posterior segment neovascularization.
    Type: Application
    Filed: February 27, 2014
    Publication date: July 17, 2014
    Applicant: Novartis AG
    Inventors: David P. Bingaman, Jon E. Chatterton
  • INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF
    Publication number: 20140194359
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 10, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: Ying Yu, Jon E. Chatterton
  • RNAi-related inhibition of TNF? signaling pathway for treatment of ocular angiogenesis
    Patent number: 8754202
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: June 17, 2014
    Assignee: Alcon Research, Ltd
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF
    Publication number: 20140135267
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
    Publication number: 20140088172
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: November 22, 2013
    Publication date: March 27, 2014
    Applicant: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
    Patent number: 8673873
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: March 18, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller